Cytosorbents (CTSO) Total Liabilities (2010 - 2026)

Cytosorbents' Total Liabilities history runs 17 years deep, the most recent figure standing at $38.4 million for Q1 2026.

• Quarterly Total Liabilities rose 5.88% year-over-year to $38.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $38.4 million (up 5.88% YoY) and the FY2025 annual result came in at $38.3 million, up 5.55% from the prior year.
• Total Liabilities was $38.4 million for Q1 2026 at Cytosorbents, roughly flat from $38.3 million in the prior quarter.
• Across five years, Total Liabilities topped out at $38.4 million in Q1 2026 and bottomed at $23.1 million in Q3 2022.
• A 5-year average of $31.6 million and a median of $29.5 million in 2023 frame the typical range for Total Liabilities.
• Peak annual rise in Total Liabilities reached 172.44% in 2022, while the deepest fall reached 5.43% in 2022.
• Cytosorbents' Total Liabilities stood at $27.9 million in 2022, then climbed by 5.81% to $29.5 million in 2023, then grew by 23.04% to $36.3 million in 2024, then advanced by 5.55% to $38.3 million in 2025, then advanced by 0.23% to $38.4 million in 2026.
• Business Quant data shows CTSO's Total Liabilities at $38.4 million in Q1 2026, $38.3 million in Q4 2025, and $36.7 million in Q3 2025.